220 related articles for article (PubMed ID: 21347224)
1. Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.
Cavenaugh JS; Awi D; Mendy M; Hill AV; Whittle H; McConkey SJ
PLoS One; 2011 Feb; 6(2):e14626. PubMed ID: 21347224
[TBL] [Abstract][Full Text] [Related]
2. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.
Bakari M; Aboud S; Nilsson C; Francis J; Buma D; Moshiro C; Aris EA; Lyamuya EF; Janabi M; Godoy-Ramirez K; Joachim A; Polonis VR; Bråve A; Earl P; Robb M; Marovich M; Wahren B; Pallangyo K; Biberfeld G; Mhalu F; Sandström E
Vaccine; 2011 Oct; 29(46):8417-28. PubMed ID: 21864626
[TBL] [Abstract][Full Text] [Related]
3. Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.
Viegas EO; Kroidl A; Munseri PJ; Missanga M; Nilsson C; Tembe N; Bauer A; Joachim A; Joseph S; Mann P; Geldmacher C; Fleck S; Stöhr W; Scarlatti G; Aboud S; Bakari M; Maboko L; Hoelscher M; Wahren B; Robb ML; Weber J; McCormack S; Biberfeld G; Jani IV; Sandström E; Lyamuya E;
PLoS One; 2018; 13(11):e0206838. PubMed ID: 30496299
[TBL] [Abstract][Full Text] [Related]
4. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
Currier JR; Ngauy V; de Souza MS; Ratto-Kim S; Cox JH; Polonis VR; Earl P; Moss B; Peel S; Slike B; Sriplienchan S; Thongcharoen P; Paris RM; Robb ML; Kim J; Michael NL; Marovich MA
PLoS One; 2010 Nov; 5(11):e13983. PubMed ID: 21085591
[TBL] [Abstract][Full Text] [Related]
5. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection.
Martinet J; Leroy V; Dufeu-Duchesne T; Larrat S; Richard MJ; Zoulim F; Plumas J; Aspord C
Hepatology; 2012 Nov; 56(5):1706-18. PubMed ID: 22707082
[TBL] [Abstract][Full Text] [Related]
6. Cloning, protein expression and immunogenicity of HBs-murine IL-18 fusion DNA vaccine.
Channarong S; Mitrevej A; Sinchaipanid N; Usuwantim K; Kulkeaw K; Chaicumpa W
Asian Pac J Allergy Immunol; 2007 Dec; 25(4):233-42. PubMed ID: 18402297
[TBL] [Abstract][Full Text] [Related]
7. Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance.
Sacherl J; Kosinska AD; Kemter K; Kächele M; Laumen SC; Kerth HA; Öz EA; Wolff LS; Su J; Essbauer S; Sutter G; Scholz M; Singethan K; Altrichter J; Protzer U
JHEP Rep; 2023 Feb; 5(2):100603. PubMed ID: 36714793
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.
Hayes P; Gilmour J; von Lieven A; Gill D; Clark L; Kopycinski J; Cheeseman H; Chung A; Alter G; Dally L; Zachariah D; Lombardo A; Ackland J; Sayeed E; Jackson A; Boffito M; Gazzard B; Fast PE; Cox JH; Laufer D
Clin Vaccine Immunol; 2013 Mar; 20(3):397-408. PubMed ID: 23345581
[TBL] [Abstract][Full Text] [Related]
9. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy.
Colombatto P; Civitano L; Bizzarri R; Oliveri F; Choudhury S; Gieschke R; Bonino F; Brunetto MR;
Antivir Ther; 2006; 11(2):197-212. PubMed ID: 16640101
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
11. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C
Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
[TBL] [Abstract][Full Text] [Related]
12. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.
Sandström E; Nilsson C; Hejdeman B; Bråve A; Bratt G; Robb M; Cox J; Vancott T; Marovich M; Stout R; Aboud S; Bakari M; Pallangyo K; Ljungberg K; Moss B; Earl P; Michael N; Birx D; Mhalu F; Wahren B; Biberfeld G;
J Infect Dis; 2008 Nov; 198(10):1482-90. PubMed ID: 18808335
[TBL] [Abstract][Full Text] [Related]
13. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
Yue W; Yuan H; Mao XR; Deng YD; Chen L
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
[TBL] [Abstract][Full Text] [Related]
14. Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.
Bauer A; Podola L; Mann P; Missanga M; Haule A; Sudi L; Nilsson C; Kaluwa B; Lueer C; Mwakatima M; Munseri PJ; Maboko L; Robb ML; Tovanabutra S; Kijak G; Marovich M; McCormack S; Joseph S; Lyamuya E; Wahren B; Sandström E; Biberfeld G; Hoelscher M; Bakari M; Kroidl A; Geldmacher C
J Virol; 2017 Sep; 91(18):. PubMed ID: 28701395
[TBL] [Abstract][Full Text] [Related]
15. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B
PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679
[TBL] [Abstract][Full Text] [Related]
16. Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand.
Khamduang W; Gaudy-Graffin C; Ngo-Giang-Huong N; Jourdain G; Moreau A; Luekamlung N; Halue G; Buranawanitchakorn Y; Kunkongkapan S; Buranabanjasatean S; Lallemant M; Sirirungsi W; Goudeau A;
PLoS One; 2012; 7(7):e42184. PubMed ID: 22860080
[TBL] [Abstract][Full Text] [Related]
17. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.
Peters BS; Jaoko W; Vardas E; Panayotakopoulos G; Fast P; Schmidt C; Gilmour J; Bogoshi M; Omosa-Manyonyi G; Dally L; Klavinskis L; Farah B; Tarragona T; Bart PA; Robinson A; Pieterse C; Stevens W; Thomas R; Barin B; McMichael AJ; McIntyre JA; Pantaleo G; Hanke T; Bwayo J
Vaccine; 2007 Mar; 25(11):2120-7. PubMed ID: 17250931
[TBL] [Abstract][Full Text] [Related]
18. Attempted therapeutic immunization in a chimpanzee chronic HBV carrier with a high viral load.
Shata MT; Pfahler W; Brotman B; Lee DH; Tricoche N; Murthy K; Prince AM
J Med Primatol; 2006 Jun; 35(3):165-71. PubMed ID: 16764675
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
[TBL] [Abstract][Full Text] [Related]
20. Phase IIb trial of
Yang FQ; Rao GR; Wang GQ; Li YQ; Xie Y; Zhang ZQ; Deng CL; Mao Q; Li J; Zhao W; Wang MR; Han T; Chen SJ; Pan C; Tan DM; Shang J; Zhang MX; Zhang YX; Yang JM; Chen GM
World J Gastroenterol; 2017 Jan; 23(2):306-317. PubMed ID: 28127204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
